Clinical trials: Eye Change
Unresectable Melanoma, Metastatic Melanoma
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
- Trial name
- NCT06940739
- Testing
- IOV-3001
- Where
- 5 sites in United States, Australia
- Volunteers
- 42 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Glaucoma; Drugs
CATS Tonometer IOP Reduction Latanoprost Verses Timolol
Topical Prostaglandin Analog vs Betablocker - Corneal Biomechanical Evaluation using CATS Tonometer Prism
- Trial name
- NCT04178863
- Testing
- CATS Tonometer, Latanoprost
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Intuor Technologies, Inc.
Chronic Allergic Conjunctivitis
Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory…
- Trial name
- NCT01730872
- Testing
- Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- ORA, Inc.
Allergic Conjunctivitis
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension, and placebo (Tears Naturale® II) in the…
- Trial name
- NCT00689078
- Testing
- Prednisolone Acetate 1%, Prednisolone Acetate 0.12%, Loteprednol Etabonate 0.2%
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- ORA, Inc.
Retinitis Pigmentosa (RP)
Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)
This is a Phase 1/2, multi-center, randomized, sham-controlled, dose-escalation study evaluating ZM-02 in patients with advanced retinitis pigmentosa (RP).
- Trial name
- PRISM (NCT07282457)
- Testing
- ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose)
- Volunteers
- 21 people
- Sponsor
- Zhongmou Therapeutics
Open-angle Glaucoma, Ocular Hypertension
Efficacy of Changing to TRAVATAN® From Prior Therapy
The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® solution without BAK (benzalkonium chloride) after changing from prior latanoprost 0.005% ophthalmic solution monotherapy in subjects with…
- Trial name
- NCT01510145
- Testing
- Travoprost 0.004% BAK-free
- Volunteers
- 191 people
- Sponsor
- Alcon Research
Corneal Endothelial Cell Changes
Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days
The objective of this study is to evaluate the effect on corneal endothelial cell density (cells/mm²) changes at 3 months when mapracorat ophthalmic suspension, 3% is administered QID (four times daily), for 14 days in healthy…
- Trial name
- NCT01736462
- Testing
- Mapracorat
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT04050865
- Testing
- Dexamethasone, 0.4mg
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- Ocular Therapeutix, Inc.
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs)
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically…
- Conditions
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA
- Trial name
- NCT06991114
- Testing
- Allogeneic NK Cells
- Where
- 52 sites in United States, Brazil and 9 more
- Volunteers
- 90 people
- Sponsor
- Artiva Biotherapeutics, Inc.
Cataract
Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens
This will be a prospective, open-label, 125 subject (maximum), two-year multicentre investigation to assess the safety, effectiveness and rotational stability of the modified 600C (axis marks) intraocular lens (IOL) in subjects…
- Trial name
- NCT02378636
- Testing
- 600S
- Where
- United Kingdom
- Sponsor
- Rayner Intraocular Lenses Limited
Healthy Male Adults
Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults
Oxytocin (OT) is a small, naturally occurring peptide currently in clinical use to stimulate lactation in breastfeeding women. The intranasal administration of OT has recently attracted attention as a potential novel treatment in…
- Trial name
- NCT01983514
- Testing
- 8IU intranasal oxytocin, 24 IU intranasal oxytocin, 1 IU intravenous oxytocin
- Where
- Norway
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- OptiNose AS
Relapsing Remitting Multiple Sclerosis (RRMS)
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context…
- Trial name
- ELIOS (NCT06733922)
- Testing
- ETNATM-ProgMS
- Where
- 14 sites in Canada
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Vision Disorders
Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers
This study is being conducted to evaluate Bausch \& Lomb PureVision Multi-Focal contact lenses compared to the Bausch \& Lomb SofLens59 contact lens when worn by adapted soft contact lens wearers on a daily wear basis.
- Trial name
- NCT00985231
- Testing
- PureVision Multi-Focal contact lenses, SofLens59 contact lens
- Where
- United States
- Volunteers
- 272 people
- Sponsor
- Bausch & Lomb Incorporated
Myopia, Progressive
Slow Myopia Progression With Different Irradiance Light
It is a prospective clinical control study on red light control myopia with specail design spectacles for 75 children in 3 groups. Study Groups with two different powers of 0.6 mW and 1.2 mW at wavelength of 650nm.
- Trial name
- NCT05881655
- Testing
- Airdoc Red Lighting Device, Special Spectacles to Control Myopia
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Beijing Airdoc Technology Co., Ltd.
Myopia
Changes in Invitro and ex Vivo Lens Metrology With Daily Wear Contact Lenses
The purpose of this study is to evaluate changes in contact lens geometry after lens wear
- Trial name
- NCT01100411
- Testing
- Air Optix Aqua, Biofinity, Proclear
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Open-Angle Glaucoma
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach.
- Trial name
- NCT05411198
- Testing
- XEN45 (Glaucoma Gel Stent)
- Where
- 25 sites in United States, Australia
- Volunteers
- 74 people
- Sponsor
- AbbVie
Allergic Conjunctivitis
Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis
The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis
- Trial name
- NCT00364091
- Testing
- R89674 0.025% ophthalmic solution
- Where
- 6 sites in United States
- Volunteers
- 365 people
- Sponsor
- Vistakon Pharmaceuticals
Glaucoma
Safety and Efficacy of Changing to DuoTrav From Prior Therapy
The purpose of this study to assess the safety and efficacy of changing to DuoTrav® from prior bimatoprost 0.03%/timolol 0.5% (used concomitantly or in a fixed combination) pharmacotherapy in uncontrolled patients with open-angle…
- Trial name
- NCT01230736
- Testing
- Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Alcon Research
Myopia, Progressive
Myopia Preventing With Distance-image Screen
This study is for testing the efficacy and safety of distance-image screens for preventing myopia in children for 12 month. Each subjects would be asked to paired test the ocular parameters between before and after 12-month…
- Trial name
- DIS (NCT06088225)
- Testing
- distance-image screen
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Beijing Airdoc Technology Co., Ltd.
Myopia
Performance of Somofilcon A Over One Week in Wearers Adapted to Omafilcon A
The objective of the study is to determine if habitual or adapted contact lens wearers of Omafilcon A can be confidently refit into Somofilcon A lenses and be successful after one week of daily wear.
- Trial name
- NCT03226353
- Testing
- somofilcon A, omafilcon A
- Where
- Canada
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- CooperVision, Inc.